Retrospective Cohort Study
Copyright ©The Author(s) 2022.
World J Clin Cases. Mar 16, 2022; 10(8): 2393-2403
Published online Mar 16, 2022. doi: 10.12998/wjcc.v10.i8.2393
Figure 3
Figure 3 Immunohistochemical indicators in patients with pancreatic adenocarcinoma. CD34-MVD, CD105-MVD, VEGF, and (α-SMA)-MVD in patients with grade III pancreatic adenocarcinoma (right) were compared with CD34-MVD, CD105-MVD, VEGF, and (α-SMA)-MVD in patients with grade I pancreatic adenocarcinoma (left). Magnification × 400.